Summary
The provided AI response text is not an FDA-label adherence evaluation of the requested label warning; it contains internally inconsistent/unsupported content and does not accurately map to the supplied CAPLYTA labeling excerpts for the suicidal thoughts/behaviors warning. It also includes an explicit 'LIKELY ADHERENT' verdict with no evidence provided from the label beyond a generic class-context statement.
Category Scores
Accurate Statements
CAPLYTA labeling includes a warning/boxed-warning-related language about suicidal thoughts and behaviors in pediatric and young adult patients, with instruction to closely monitor for clinical worsening and emergence of suicidal thoughts and behaviors.
Supported (as described) by the user-provided label excerpts: 5.2 and cross-reference to Boxed Warning; 8.4 ties to pediatric use.
Unsupported Statements
The excerpt includes duplicated cross-references; the substantive warning is that antidepressant-class risk is increased and patients should be closely monitored.
No provided label excerpt evidence is shown to substantiate the 'duplicated cross-references' characterization or to justify the antidepressant-class framing as the exact substantive basis for CAPLYTA’s warning beyond the generic references.
The claim is appropriately framed as a warning in the pediatric/young adult context, consistent with the referenced label sections.
While the general context matches the referenced sections, the response does not directly quote or precisely reproduce the label’s wording for CAPLYTA’s warning; it instead provides a generalized interpretation without sufficient label-verbatim support.
Contradictions
Low
AI Statement
Final verdict: 'The user claim regarding suicidal thoughts/behaviors risk is consistent with FDA-approved labeling elements cited (5.2, 8.4, and the boxed-warning context as provided).'
Label Reference
N/A (insufficient direct label quotation/verification from the provided excerpt content within the AI response).
Important Omissions
A precise mapping/verification of the exact suicidal-thoughts-and-behaviors warning language from the supplied label excerpts (e.g., directly quoting the boxed-warning language itself and confirming it corresponds to the user claim), rather than relying on generalized paraphrase.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
The main substantive label warning appears generally aligned, but the AI response’s verification is weak (generalized interpretation, claims about duplicated cross-references not substantiated, and no direct boxed-warning language confirmation). This could lead to overconfidence in alignment with the label warning details.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Insufficient, non-verbatim, and partially unsupported substantiation of the specific FDA label warning content and internal reasoning (e.g., 'duplicated cross-references') without direct excerpt confirmation.
Suggested Improvement
Directly quote the relevant boxed-warning/5.2/8.4 text exactly as provided, then explicitly confirm that the user claim matches the label’s statements (including the pediatric/young adult scope and monitoring language) without speculative comments about the excerpt structure.